US industry keeps keen eye on drug bill's device content
This article was originally published in Clinica
Executive Summary
Several items on the device industry's Medicare agenda are well on their way to adoption. They were included in both of the Medicare Prescription Drug Bills that passed both the US House and the US Senate last week, meaning they are all but certain to be incorporated in the final bill to be ironed out in a House and Senate conference committee which is likely to meet later this month.